SCHEMBL9932034

SCHEMBL9932034

Cn1cc(-c2ccnc3c2C(=O)N(CCC#N)C3)c(-c2ccc(F)cc2)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 9/20 0.71
MAPK14 Q16539 6/20 0.70
CSNK1E P49674 6/20 0.70
MAP4K4 O95819 2/20 0.70
MAPK9 P45984 2/20 0.70
CSNK1A1 P48729 2/20 0.70
NUAK1 O60285 1/20 0.70
ROCK2 O75116 1/20 0.70
LCK P06239 1/20 0.70
MAPK8 P45983 1/20 0.70
GSK3B P49841 1/20 0.70
MAP2K1 Q02750 1/20 0.70
MINK1 Q8N4C8 1/20 0.70
AURKB Q96GD4 1/20 0.70
MAPK11 Q15759 5/20 0.47
MAPK13 O15264 3/20 0.47
MAPK12 P53778 3/20 0.47
KCNH2 Q12809 3/20 0.47
MAPT P10636 4/20 0.42
HPGD P15428 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933303 0.88 CSNK1D (0.77) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL18575627 0.86 CSNK1D (0.71) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL18575626 0.85 CSNK1D (0.73) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL18575622 0.85 CSNK1D (0.69) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL9933664 0.85 CSNK1D (0.71) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL9932752 0.85 CSNK1D (0.71) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL18575624 0.85 CSNK1D (0.71) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL9933184 0.84 CSNK1D (0.68) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL18575617 0.84 CSNK1D (0.68) CSNK1DMAPK14CSNK1EMAP4K4MAPK9
SCHEMBL9933710 0.84 CSNK1D (1.00) CSNK1DMAPK14CSNK1EMAP4K4MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181133-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS Pfizer Inc (US) 2017-06-21 EP claimed
EP-2654750-B1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS PFIZER (US) 2017-03-08 EP claimed
EP-2654750-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS Pfizer Inc (US) 2013-10-30 EP claimed
US-8536164-B2 Fused pyridine compounds as casein kinase inhibitors PFIZER INC. (US) 2013-09-17 US claimed
WO-2012085721-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS PFIZER INC. (US) 2012-06-28 WO claimed
US-20120157440-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS PFIZER INC 2012-06-21 US claimed
EP-3181133-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS Pfizer Inc (US) 2017-06-21 EP disclosed
EP-2654750-B1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS PFIZER (US) 2017-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157440-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS CSNK1A1, CSNK1A1L, CSNK1E CSNK1D 10/4885MAPK14 270/4885CSNK1E 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.